Amivantamab

• Phase II trial of amivantamab plus monochemotherapy in platinum unfit NSCLC patients with EGFR exon20 insertion mutations Pending
  2025-520676-26-00 Phase II 1 country Fondazione Ricerca Traslazionale
• A Study to Assess Adverse Events, Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Ad… Recruiting
  2025-521124-29-00 Phase II/III 9 countries AbbVie Deutschland GmbH & Co. KG
• A Study of Amivantamab in Addition to Standard of Care Agents Compared with Standard of Care in Participants With Recurrent/Metastatic Head … Recruiting
  2025-521917-24-00 Phase III 12 countries Janssen Cilag International
• A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous… Recruiting
  2025-520730-28-00 Phase II 9 countries Janssen Cilag International
• Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With Recurrent KRAS/NRAS and BRAF Wild-type Colorectal Cancer Recruiting
  2024-513853-66-00 Phase III 10 countries Janssen Cilag International
• Amivantamab + Chemotherapy Versus Cetuximab + Chemotherapy in Treatment-naïve Participants with KRAS/NRAS and BRAF Wild-type Colorectal Canc… Recruiting
  2024-513852-13-00 Phase III 9 countries Janssen Cilag International
• A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Other Therapeutic Agents in Participants with Head … Recruiting
  2023-508418-40-00 Phase I/II 4 countries Janssen Cilag International
• Preoperative amivantamab or amivantamab and carboplatin/pemetrexed treatment in patients with resectable non-small-cell lung cancer harborin… Recruiting
  2023-505662-28-00 Phase II 3 countries Universitaetsklinikum Essen AöR
• Window-of-opportunity umbrella platform trial of short-course pre-operative targeted treatments in patients with molecularly selected and re… Recruiting
  2022-501308-90-00 Phase II 1 country Fondazione GONO G.I.
• A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid … Recruiting
  2023-505065-91-00 Phase II 4 countries Janssen - Cilag International
• A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or … Recruiting
  2023-506517-22-00 Phase I/II 4 countries Janssen - Cilag International
• Improving public cancer care by implementing precision medicine in Norway Recruiting
  2023-507894-16-00 Phase II 1 country Oslo University Hospital HF
• A modular multi-Basket trial to improve personalized medicine in cancer patients Recruiting
  2024-514238-19-00 Phase II 6 countries Vall D Hebron Institute Of Oncology
• DRUP trial Recruiting
  2023-509152-33-00 Phase II 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
• A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer (PolyDamas) Ended
  2022-501452-29-00 Phase I/II 3 countries Janssen - Cilag International
• A Clinical Study to Evaluate the Safety and Efficacy of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small … Ended
  2023-508256-19-00 Phase I/II 5 countries Janssen Cilag International
• Randomized open-label Phase 2 trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adver… Ended
  2023-505863-35-00 Phase II 3 countries Janssen - Cilag International
• ETOP 18-21 AMAZE-lung: A clinical study exploring the effect of amivantamab and lazertinib plus bevacizumab treatment, in people diagnosed w… Ended
  2024-512288-29-00 Phase II 4 countries ETOP IBCSG Partners Foundation
• A Clinical Study of Lazertinib with Subcutaneous Amivantamab Compared with Intravenous Amivantamab in Patients with EGFR-mutated Advanced or… Ended
  2024-512045-16-00 Phase III 6 countries Janssen Cilag International
• A Clinical Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in … Ended
  2023-506518-33-00 Phase III 12 countries Janssen - Cilag International
• A Randomized, Open-label Phase 3 Study of Combination Amivantamab and CarboplatinPemetrexed Therapy, Compared with Carboplatin-Pemetrexed, i… Ended
  2023-506033-29-00 Phase III 8 countries Janssen - Cilag International
• A Clinical Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients … Ended
  2023-506576-27-00 Phase III 9 countries Janssen - Cilag International
• Evaluation of Amivantamab Infusion Related Reaction Mitigation Ended
  2023-506578-11-00 Phase II 2 countries Janssen - Cilag International

Showing 1–23 of 23 trials